Almost everyone else thinks that the drug increases risk of heart problems.
A Food and Drug Administration safety scientist today said that "GlaxoSmithKline Plc’s diabetes pill Avandia should be removed from the market because of heart risks," according to Bloomberg.
On May 27, a prominent researcher wrote in The New England Journal of Medicine that the drug increased the risk of heart attack.
GSK wants to believe that the drug is OK, because if it is pulled from the US market its shareholders get hammered. Its stock is near 52-week lows, and it appears that it is going to get worse.
Douglas A. McIntyre